Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
26 avr. 2023 17h00 HE
|
Aravive, Inc.
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Appoints Carolina Petrini as Chief Commercial Officer
11 avr. 2023 07h05 HE
|
Aravive, Inc.
HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
15 mars 2023 07h00 HE
|
Aravive, Inc.
HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer
28 févr. 2023 16h05 HE
|
Aravive, Inc.
Dose escalation portion of ongoing Phase 1b/2 pancreatic adenocarcinoma trial initiated, with preliminary results expected in 2H 2023 HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc....
Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
13 févr. 2023 17h00 HE
|
Aravive, Inc.
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
04 janv. 2023 07h05 HE
|
Aravive, Inc.
Topline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late...
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
29 nov. 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive To Participate in Piper’s 34th Annual Healthcare Conference
21 nov. 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement
16 nov. 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
10 nov. 2022 07h00 HE
|
Aravive, Inc.
Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic AdenocarcinomaSecured Funding to Take the Company Beyond the PROC...